M. Taylor Burtis
Keine laufenden Positionen mehr
Profil
M.
Taylor Burtis has been Vice President-Regulatory, Quality and Compliance of Novelos Therapeutics, Inc. since July 2005.
Previously, she was Senior Director-Regulatory Affairs of Therion Biologics from October 2004 to June 2005 and Antigenics from November 2003 to September 2004.
Ms. Burtis was Associate Director-Worldwide Regulatory Affairs of Wyeth BioPharma from May 2000 to October 2003, Senior Manager-Regulatory Affairs of Genentech from 1996 to April 2000, FDA Consumer Safety Officer in the Office of Compliance at the Center for Biologics Evaluation and Research and Medical Research Manager of the Boston Veterans Administration Center from 1991 to 1992.
She has more than 25 years of regulatory and senior management experience.
Ms. Burtis was Research Lab Manager of Children's Hospital from 1987 to 1991, Laboratory Director of Brigham & Women's Hospital and Technical Specialist International Liaison with the American Red Cross from 1980 to 1985.
She received a BS degree in Biology from Framingham State College and an MBA degree in Operations and Strategy from Simmons College.
Ehemalige bekannte Positionen von M. Taylor Burtis
| Unternehmen | Position | Ende |
|---|---|---|
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | General Counsel | 13.05.2008 |
Ausbildung von M. Taylor Burtis
| Framingham State College | Undergraduate Degree |
| Simmons University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
